12月22日，格隆汇于线上举办"科技赋能·资本破局"分享会。在格隆汇"金格奖"年度卓越公司评选中， 东曜药业(1875.HK)凭借其在生物医药领域的持续创新力与稳健成长表现，荣获"年度卓越生物医药企 业"奖项。 据悉，"年度卓越生物医药企业"奖项聚焦于企业的研发创新能力、核心产品竞争力、商业化进展及可持 续发展潜力，旨在表彰在技术突破、管线布局、临床价值及市场前景方面表现突出，并为行业与投资者 创造长期价值的优质生物科技公司。评选综合了行业专家评审、定量数据分析及市场反馈等多维度考 量。 在当前生物科技行业聚焦差异化创新与精益发展的背景下，东曜药业获此殊荣，标志着市场对其独特发 展路径与平台价值的深度认可。 一体化生态布局，稳健迈向价值兑现期 凭借前瞻的战略卡位与扎实的平台能力，东曜药业如今已将各项前瞻布局转化为切实的财务表现与成长 动能，并勾勒出一条清晰的加速增长的价值曲线。 那么，东曜药业做对了什么？ 01 打造差异化ADC技术平台，构筑核心竞争力壁垒 从战略视角来看，东曜药业的独到之处，首先在于其前瞻性地聚焦ADC这一技术壁垒高、市场前景广 阔的黄金赛道，不仅深耕ADC自主研发，更成功构建了覆盖研发、工 ...

Core Viewpoint - Dongyao Pharmaceutical (1875.HK) has been awarded the "Annual Outstanding Biopharmaceutical Company" for its continuous innovation and stable growth in the biopharmaceutical sector, reflecting market recognition of its unique development path and platform value [1][3]. Group 1: Company Achievements - The "Annual Outstanding Biopharmaceutical Company" award focuses on R&D innovation capability, core product competitiveness, commercialization progress, and sustainable development potential, recognizing companies that create long-term value for the industry and investors [3]. - Dongyao Pharmaceutical has established a differentiated ADC (Antibody-Drug Conjugate) technology platform, creating a competitive barrier and becoming one of the few global CDMO service companies with a full industry chain for ADCs [4][5]. Group 2: Strategic Positioning - The company has strategically focused on the ADC sector, which has high technical barriers and broad market prospects, successfully building an integrated platform covering R&D, process development, clinical trials, regulatory approval, and commercial production [4][5]. - Dongyao's platform ecosystem enhances its competitive advantage by collaborating with various domestic and international pharmaceutical companies, creating a virtuous cycle of internal R&D and external service empowerment [5]. Group 3: Financial Performance - Dongyao Pharmaceutical has translated its strategic positioning into tangible financial performance, with its commercialized product, Puxintin® (Bevacizumab Injection), expanding globally and providing stable cash flow [7]. - The CDMO business, particularly in the ADC field, has seen a continuous increase in orders, contributing to revenue growth and optimizing the company's overall profit model, with 16 new projects added by mid-2025, including 14 ADC projects [8]. Group 4: Future Outlook - The recognition of Dongyao Pharmaceutical as an outstanding biopharmaceutical company underscores the market's affirmation of its ADC technology platform and full industry chain capabilities [10]. - The company's development path illustrates that true excellence in the biopharmaceutical industry requires not only cutting-edge scientific insights but also the ability to convert technological advantages into sustainable commercialization and platform ecosystems [10].